What You Should Know:

你应该知道的：

–

–

Catalio Capital Management, LP (“Catalio”),

卡塔利奥资本管理公司，LP（“卡塔利奥”），

a healthcare investment firm, today announced the successful close of its fourth venture fund, Catalio Nexus Fund IV (“Fund IV”), with over $400M in commitments across the Fund and its related co-investment vehicles.

一家医疗保健投资公司，今天宣布其第四只风险基金 Catalio Nexus Fund IV（“基金 IV”）成功结束募资，该基金及其相关共同投资工具共获得超过 4 亿美元的承诺资金。

– Launched in 2020 by Co-Founders George Petrocheilos and Dr. Jacob Vogelstein, Catalio currently manages $2B in assets across its private equity, private credit, and public equities strategies.

– Catalio 由联合创始人 George Petrocheilos 和 Jacob Vogelstein 博士于2020年创立，目前在其私募股权、私人信贷和公共股票策略中管理着20亿美元的资产。

A Differentiated Investment Approach in Healthcare

医疗保健领域的差异化投资方法

Catalio’s core investment approach centers on identifying and supporting transformative healthcare companies that are spun out of leading academic institutions and led by repeat founders with deep scientific expertise. Their Nexus funds have invested in over 80 private companies since the firm’s inception five years ago.

Catalio的核心投资策略聚焦于识别和支持那些从领先的学术机构分拆出来、由具有深厚科学专业知识的连续创业者领导的变革型医疗保健公司。自五年前公司成立以来，其Nexus基金已投资了80多家私营企业。

Catalio has also successfully sold or taken public a number of businesses over the years, consistently making distributions to its limited partners every year since its founding..

多年来，Catalio 还成功出售或上市了多家企业，自成立以来每年持续向其有限合伙人进行分配。

Fund IV’s Early Investments and Strategic Focus

基金四的早期投资与战略重点

To date, Fund IV has already made 16 investments, showcasing Catalio’s commitment to partnering with world-class teams and building category-defining life sciences businesses across all stages, from inception to IPO and beyond.

迄今为止，基金IV已经进行了16项投资，展示了Catalio致力于与世界级团队合作，并在各个阶段（从创立到IPO及以后）打造定义类别的生命科学企业的承诺。

Recent highlights in Fund IV’s investment portfolio include:

基金IV投资组合的近期亮点包括：

Cancer Diagnostics:

癌症诊断：

Co-leading PinkDx’s $40 million Series A fundraise, focused on developing diagnostics for gynecological cancers.

共同领导 PinkDx 4000 万美元的 A 轮融资，专注于开发妇科癌症诊断技术。

AI-Enabled Drug Discovery:

人工智能辅助药物发现：

Investing in the Series A financing of Superluminal Medicines, expanding Catalio’s portfolio in AI-enabled drug discovery.

投资Superluminal Medicines的A轮融资，扩大Catalio在人工智能辅助药物发现领域的投资组合。

New Company Launches (Immunology & Inflammation):

新公司成立（免疫学与炎症）：

Launching Rhapsogen, co-founded by Catalio Venture Partner Dr. Jeffrey Ravetch at Rockefeller University, and TBD Pharma, co-founded by Catalio Venture Partner Dr. Bert Vogelstein at Johns Hopkins University.

推出由Catalio风险合伙人Dr. Jeffrey Ravetch在洛克菲勒大学共同创立的Rhapsogen，以及由Catalio风险合伙人Dr. Bert Vogelstein在约翰霍普金斯大学共同创立的TBD Pharma。

Late-Stage Investments:

晚期投资：

Participating in Imperative Care’s $150M Series E financing (a medical device company), a PIPE for Protara Therapeutics (an oncology company), and Alentis Therapeutics’ $180M Series D financing (a company developing antibody drug conjugates for oncology indications).

参与了 Imperative Care 的 1.5 亿美元 E 轮融资（一家医疗设备公司）、Protara Therapeutics 的 PIPE 融资（一家肿瘤学公司），以及 Alentis Therapeutics 的 1.8 亿美元 D 轮融资（一家为肿瘤适应症开发抗体药物偶联物的公司）。

“We are grateful for the continued confidence and strong support we received for Fund IV from both new and existing high caliber investors,” said Olga Maltseva, Partner & Head of Operations at Catalio. “These new funds will allow Catalio to continue taking advantage of opportunities in a historic buyer’s market in biotech, and to keep distinguishing ourselves as a leading innovative healthcare investor around the globe.”.

“我们感谢新老高素质投资者对第四基金的持续信任与大力支持，”Catalio的合伙人兼运营主管奥尔加·马尔采娃表示。“这些新资金将使Catalio能够继续利用生物技术领域历史性的买方市场机遇，并在全球范围内巩固我们作为领先的创新医疗保健投资者的地位。”